Alglucosidase alfa (Lumizyme) for Pompe disease
Customize your policy alerts
Sign up for Baylor Scott & White Health Plan Policy 316 alerts
Get alerted when Policy 316 changes without checking for updates manually.
Monitor payer policy activity
Defines prior authorization, medical necessity criteria, and renewal criteria for coverage of alglucosidase alfa (Lumizyme) for treatment of infantile- and late-onset Pompe disease for Baylor Scott & White Health Plan members.
Updated authorization duration to 12 months.
Removed Medicare NCD/LCD Interqual statement for clarity in a previous update.
Coverage and Medical Necessity Criteria
inv-01: Initial requests
Covered when ALL of the following are met
Prior authorization required.
inv-02: Renewal requests
Renewal covered when ALL of the following are met
Authorization duration: 12 months.
inv-03: Experimental / Investigational
All requests will be reviewed by a clinical pharmacist and medical director.
Alglucosidase alfa (Lumizyme) must not be administered in combination with any other enzyme replacement therapy for Pompe disease. Examples of prohibited concomitant ERTs include avalglucosidase alfa (Nexviazyme) and cipaglucosidase alfa with miglustat (Pombliti with Opfolda). Requests for combination use may be denied as they do not meet the policy’s coverage criteria.
Use of alglucosidase alfa (Lumizyme) for any indications other than Pompe disease, or for clinical scenarios that do not meet the specific coverage criteria listed in this policy, is considered experimental and investigational because effectiveness has not been established. Such requests will be reviewed by a clinical pharmacist and medical director and are not covered as medically necessary.
Billing Codes and Dosing Limits
| J0221 | Injection, alglucosidase alfa, (lumizyme), 10 MG |
| E74.02 | Pompe Disease |
Prior Authorization, Documentation, and Provider Guidance
Prior Authorization Required
Prior authorization required — prior authorization is required for alglucosidase alfa (Lumizyme). Initial requests must meet diagnostic and prescriber criteria, dosing limits, and other requirements; renewal requests must document clinical benefit. Authorization duration: 12 months.
- Initial requests: diagnosis confirmed by enzyme assay (GAA deficiency) or genetic testing; prescribed by or in consultation with a metabolic specialist, geneticist, or physician experienced in Pompe disease; dose ≤ 20 mg/kg every 2 weeks; for late-onset Pompe disease (LOPD) include baseline % predicted FVC if respiratory involvement or baseline motor function (6MWT); not to be used in combination with other ERTs (e.g., avalglucosidase alfa [Nexviazyme], cipaglucosidase alfa + miglustat [Pombliti with Opfolda]).
- Renewal requests: must meet initial criteria and demonstrate positive response or slowed disease progression in at least one area (motor function such as 6MWT, cardiac function, pulmonary function such as % predicted FVC, or delayed death). Authorization duration: 12 months.
- All requests are reviewed by a clinical pharmacist and medical director.
Step Therapy / Comparative Agents
Step therapy / comparative agents — no step-therapy is required for alglucosidase alfa; providers should be aware of other approved enzyme replacement therapies for LOPD.
- No formulary step edits required prior to alglucosidase alfa for covered indications.
- Comparative agents for LOPD include avalglucosidase alfa-ngpt (Nexviazyme) and cipaglucosidase alfa-atga with miglustat (Pombliti with Opfolda); these alternatives are for provider awareness and may have different approval considerations.
- Newer therapies have limited or no approval for infantile-onset Pompe disease (IOPD); check indication-specific evidence when considering alternatives.
Required Documentation
Required documentation — medical records must document the diagnosis and baseline status as applicable.
- Diagnosis documentation: enzyme assay confirming GAA deficiency OR genetic testing showing pathogenic GAA variants.
- Prescriber documentation: prescription by or documentation of consultation with a metabolic specialist, geneticist, or physician experienced in Pompe disease.
- Baseline documentation for LOPD: % predicted FVC if respiratory involvement and/or motor function assessment (6MWT).
- Dosing documentation: proposed dose and schedule (must not exceed 20 mg/kg every 2 weeks).
- Medication history: documentation that alglucosidase alfa will not be used concurrently with other ERTs for Pompe disease.
Triggers for Denial
Triggers for denial — requests lacking required diagnostic, prescriber, dosing, or clinical-response documentation will be denied.
- No confirmed diagnosis of Pompe disease by enzyme assay or genetic testing.
- Not prescribed by or not in consultation with an appropriate specialist (metabolic specialist, geneticist, or physician experienced in Pompe disease).
- Proposed dose exceeds 20 mg/kg every 2 weeks.
- Concurrent use with another enzyme replacement therapy for Pompe disease.
- For renewals: absence of documentation showing clinical benefit or slowed disease progression (no improvement or stabilization in motor function, cardiac function, pulmonary function, or survival).
- Requests for indications considered experimental/investigational (any use not supported by evidence for Pompe disease) will be denied.
Clinical Background
Pompe disease (acid maltase deficiency) is an autosomal recessive disorder caused by deficient activity of the lysosomal acid alpha‑glucosidase (GAA) enzyme, leading to accumulation of glycogen within lysosomes of cardiac, respiratory, and skeletal muscle. Clinical presentation ranges from infantile‑onset Pompe disease (IOPD), characterized by early and severe cardiomyopathy and high mortality, to late‑onset Pompe disease (LOPD), which presents later with progressive skeletal and respiratory muscle weakness and less prominent cardiac involvement. Recombinant human alglucosidase alfa (Lumizyme) is an enzyme replacement therapy used to treat both IOPD and LOPD.
Key Definitions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.